Literature DB >> 32652267

Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR/NF-κB/IDO-1 signaling.

Anderson Camargo1, Ana P Dalmagro2, Julia M Rosa3, Ana Lúcia B Zeni2, Manuella P Kaster1, Carla I Tasca1, Ana Lúcia S Rodrigues4.   

Abstract

Augmentative treatment is considered the best second-option when a first-choice drug has partial limitations, particularly by allowing antidepressant dose reduction. Considering that ketamine has significant knock-on effects, this study investigated the effects of single coadministration with subthreshold doses of ketamine plus guanosine in a corticosterone (CORT)-induced animal model of depression and the role of anti-inflammatory and antioxidant pathways. CORT administration (20 mg/kg, p.o., for 21 days) increased the immobility time in the tail suspension test (TST) and the grooming latency in the splash test (SPT), as well as reduced the total time of grooming in the SPT. These behavioral alterations were accompanied by impaired hippocampal slices viability, elevated immunocontent of nuclear factor-kappa B (NF-κB) and indoleamine-2,3-dioxygenase 1 (IDO-1), and reduced immunocontent of glucocorticoids receptor (GR), glutamate transporter (GLT-1), nuclear factor-erythroid 2-related factor 2 (Nrf2), and heme oxygenase-1 (HO-1) in the hippocampus. CORT also decreased the thioredoxin reductase activity in the hippocampus, while reduced the glutathione reductase activity and non-protein thiols levels in both hippocampus and prefrontal cortex. In addition, elevated content of malondialdehyde and protein carbonyl was also observed in the hippocampus and prefrontal cortex of CORT-treated mice. Of note, a single administration of ketamine (0.1 mg/kg, i.p.) plus guanosine (0.01 mg/kg, p.o.) attenuated the depressive-like behavior and hippocampal slices impairments induced by CORT. The behavioral response obtained by the combined administration of these drugs was paralleled by the reestablishment of the CORT-induced molecular alterations on hippocampal GR, NF-κB, IDO-1, and GLT-1 immunocontent. Moreover, CORT-induced alterations on the antioxidant enzyme activity and oxidative stress markers were partially restored by ketamine plus guanosine treatment. Taken together, these findings suggest that guanosine might potentiate the effects of ketamine on inflammatory and oxidative markers that are elevated in depression.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Augmentation; depression; guanosine; ketamine; stress

Year:  2020        PMID: 32652267     DOI: 10.1016/j.neuint.2020.104797

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  4 in total

1.  The antidepressant-like effect of guanosine involves the modulation of adenosine A1 and A2A receptors.

Authors:  Anderson Camargo; Luis E B Bettio; Priscila B Rosa; Julia M Rosa; Glorister A Altê; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2022-09-27       Impact factor: 3.950

2.  The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity.

Authors:  Melody J Y Kang; Emily Hawken; Gustavo Hector Vazquez
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

3.  Ketamine, but not fluoxetine, rapidly rescues corticosterone-induced impairments on glucocorticoid receptor and dendritic branching in the hippocampus of mice.

Authors:  Daiane B Fraga; Anderson Camargo; Gislaine Olescowicz; Dayane Azevedo Padilha; Francielle Mina; Josiane Budni; Patricia S Brocardo; Ana Lúcia S Rodrigues
Journal:  Metab Brain Dis       Date:  2021-05-05       Impact factor: 3.584

4.  Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway.

Authors:  Anderson Camargo; Ana Paula Dalmagro; Daiane B Fraga; Julia M Rosa; Ana Lúcia B Zeni; Manuella P Kaster; Ana Lúcia S Rodrigues
Journal:  Psychopharmacology (Berl)       Date:  2021-08-03       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.